INmune Bio (INMB) · After Hours PM ET 08/30/ $ %. Previous Close · $ · ; % · Volume: , · Volume % Chg: 44% · Get a. The average one-year price target for INmune Bio, Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price target is. The 1 analysts offering price forecasts for INmune Bio have a median target of , with a high estimate of and a low estimate of The median. After Hours: $ (%) ; Puma Biotechnology Inc. $ PBYI % ; Applied Therapeutics Inc. $ APLT % ; Verastem Inc. $ VSTM %. Inmune Bio Stock Forecast FAQ What is INMB's forecast return on equity (ROE) for ? (NASDAQ: INMB) forecast ROE is N/A, which is considered weak. If.
INmune Bio Inc. (INMB) Stock Performance ; INmune Bio (INMB). , , , ; BSE Sensex · , , , INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune. Investors. We rely on the public markets for the development of our novel therapies. Stock Information. NASDAQ: INMB. Market Price: $ INmune Bio ; Status. Public ; Employees. Employees ; Stock Symbol. INMB. Stock Symbol ; Share Price. $ INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune. What is INmune Bio, Inc. (INMB)'s stock price history? Over the last year, INmune Bio, Inc.'s stock price has decreased by %. INmune Bio, Inc. is currently. View INmune Bio, Inc. INMB stock quote prices, financial information, real-time forecasts, and company news from CNN. INmune Bio (NASDAQ:INMB) Stock Quotes, Forecast and News Summary ; Day Range, $ - $ ; 52 Wk Range, - ; Market Cap, $M ; P/E Ratio, -. INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight. INmune Bio Inc. ; Volume, K ; Market Value, $M ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A. View today's INmune Bio Inc stock price and latest INMB news and analysis. Create real-time notifications to follow any changes in the live stock price.
Stock analysis for Inmune Bio Inc (INMB:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Shares of INmune Bio Inc. plummeted % toward a month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an. Discover real-time INmune Bio Inc. Common stock (INMB) stock prices, quotes, historical data, news, and Insights for informed trading and investment. As of July 26, , INMB stock price climbed to $ with , million shares trading. What is Inmune Bio's Beta? INMB has a beta of , meaning. INmune Bio (NASDAQ:INMB) Second Quarter Results Key Financial Results Net loss: US$m (loss widened by INmune Bio Inc ; Apr, Initiated, B. Riley Securities, Buy, $29 ; Jan, Reiterated, Maxim Group, Buy, $16 → $ INmune Bio Inc INMB:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date02/14/24 · 52 Week Low · 52 Week. Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Over-Allotment Option. INmune Bio (NASDAQ:INMB) Stock Quotes, Forecast and News Summary ; Day Range, $ - $ ; 52 Wk Range, - ; Market Cap, $M ; P/E Ratio, -.
INmune Bio Inc. ; , , , , ; , , , , The average price target is $ with a high forecast of $ and a low forecast of $ The average price target represents a % change from the. Track INmune Bio Inc (INMB) Stock Price, Quote, latest community messages, chart, news and other stock related information. A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. INmune Bio Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer.
The INmune Bio Approach to Alzheimer's Disease
On Friday, INmune Bio Inc (INMB:NAQ) closed at , % above its week low of , set on Aug 21, week range. Today. Aug 21 INmune Bio Inc Performance ; Diluted EPS (TTM), ; Revenue Growth YOY, ; Earnings Growth YOY, 0 ; Profit margin, 0. INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies that leverage the body's innate immune.